Cargando…
Classification, diagnosis, and management of conjunctival lymphoma
Lymphoma is a malignant lymphoproliferative tumor that can involve the conjunctiva. Approximately 5–15% of all extranodal lymphomas are found in the ocular adnexal region, with approximately 25% of those involving the conjunctiva. Ninety-eight percent of conjunctival lymphomas arise from B-lymphocyt...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660942/ https://www.ncbi.nlm.nih.gov/pubmed/31372366 http://dx.doi.org/10.1186/s40662-019-0146-1 |
_version_ | 1783439387287093248 |
---|---|
author | Tanenbaum, Rebecca E. Galor, Anat Dubovy, Sander R. Karp, Carol L. |
author_facet | Tanenbaum, Rebecca E. Galor, Anat Dubovy, Sander R. Karp, Carol L. |
author_sort | Tanenbaum, Rebecca E. |
collection | PubMed |
description | Lymphoma is a malignant lymphoproliferative tumor that can involve the conjunctiva. Approximately 5–15% of all extranodal lymphomas are found in the ocular adnexal region, with approximately 25% of those involving the conjunctiva. Ninety-eight percent of conjunctival lymphomas arise from B-lymphocytes. The most common subtype of conjunctival lymphoma is extranodal marginal zone lymphoma (80%), followed by follicular lymphoma (8%), diffuse large B-cell lymphoma (3%) and mantle cell lymphoma (3%). Natural killer and T cells (NK/T) are rare causes of lymphoma. While most conjunctival lymphomas are localized to the ocular adnexa at the time of presentation, systemic examination and management are of key importance in the long-term care of the patient. This review outlines the classification, etiology, presentation, diagnosis, and management of conjunctival lymphoma. The novel use of high resolution optical coherence tomography, both as a diagnostic tool and as a means for ongoing evaluation during treatment, is illustrated. Treatment options discussed include external beam radiation, chemotherapy, immunotherapy, antibiotic therapy, and combination regimens. Future investigation of the etiology and pathogenesis of conjunctival lymphoma is expected to reveal opportunities for innovative and individualized therapeutic agents. Collaboration between multiple disciplines is key in the advancement of the field. |
format | Online Article Text |
id | pubmed-6660942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66609422019-08-01 Classification, diagnosis, and management of conjunctival lymphoma Tanenbaum, Rebecca E. Galor, Anat Dubovy, Sander R. Karp, Carol L. Eye Vis (Lond) Review Lymphoma is a malignant lymphoproliferative tumor that can involve the conjunctiva. Approximately 5–15% of all extranodal lymphomas are found in the ocular adnexal region, with approximately 25% of those involving the conjunctiva. Ninety-eight percent of conjunctival lymphomas arise from B-lymphocytes. The most common subtype of conjunctival lymphoma is extranodal marginal zone lymphoma (80%), followed by follicular lymphoma (8%), diffuse large B-cell lymphoma (3%) and mantle cell lymphoma (3%). Natural killer and T cells (NK/T) are rare causes of lymphoma. While most conjunctival lymphomas are localized to the ocular adnexa at the time of presentation, systemic examination and management are of key importance in the long-term care of the patient. This review outlines the classification, etiology, presentation, diagnosis, and management of conjunctival lymphoma. The novel use of high resolution optical coherence tomography, both as a diagnostic tool and as a means for ongoing evaluation during treatment, is illustrated. Treatment options discussed include external beam radiation, chemotherapy, immunotherapy, antibiotic therapy, and combination regimens. Future investigation of the etiology and pathogenesis of conjunctival lymphoma is expected to reveal opportunities for innovative and individualized therapeutic agents. Collaboration between multiple disciplines is key in the advancement of the field. BioMed Central 2019-07-27 /pmc/articles/PMC6660942/ /pubmed/31372366 http://dx.doi.org/10.1186/s40662-019-0146-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Tanenbaum, Rebecca E. Galor, Anat Dubovy, Sander R. Karp, Carol L. Classification, diagnosis, and management of conjunctival lymphoma |
title | Classification, diagnosis, and management of conjunctival lymphoma |
title_full | Classification, diagnosis, and management of conjunctival lymphoma |
title_fullStr | Classification, diagnosis, and management of conjunctival lymphoma |
title_full_unstemmed | Classification, diagnosis, and management of conjunctival lymphoma |
title_short | Classification, diagnosis, and management of conjunctival lymphoma |
title_sort | classification, diagnosis, and management of conjunctival lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660942/ https://www.ncbi.nlm.nih.gov/pubmed/31372366 http://dx.doi.org/10.1186/s40662-019-0146-1 |
work_keys_str_mv | AT tanenbaumrebeccae classificationdiagnosisandmanagementofconjunctivallymphoma AT galoranat classificationdiagnosisandmanagementofconjunctivallymphoma AT dubovysanderr classificationdiagnosisandmanagementofconjunctivallymphoma AT karpcaroll classificationdiagnosisandmanagementofconjunctivallymphoma |